NEW YORK, Aug. 19 (GenomeWeb News) - Gene Logic has entered into an agreement with the US Food and Drug Administration's Center for Drug Evaluation and Research to use its gene expression data from control and treated rats to evaluate toxicogenomics data, the company said today.
The agreement is designed to assist the FDA in assessing quality of genomics data that is part of new drug submissions. The company said the results of the research will be publicly available.
"We are excited about working closely with Gene Logic scientists in the pursuit of our shared vision of evaluating standards which may become critical for future regulatory submissions," Karol Thompson, who will be the primary CDER investigator on this project, said in a statement. "In building on this agreement, we look forward to additional joint research efforts with Gene Logic aimed at increasing the safety and efficacy profile of drugs."